scieee Science in your language
[en] (orig)

Peroxisome proliferator-activated receptor alpha and gamma agonists differently regulate classical and alternative macrophage activation

Abstract

Peroxisome proliferator-activated receptor (PPAR) agonists, fibrates and thiazolidinediones, are commonly used drugs in the treatment of dyslipidemia and diabetes. Their targets, PPARα and PPARγ, have also been shown to have a role in the regulation of inflammatory responses linking metabolism and inflammation. In the present study we investigated the effects of PPAR agonists on macrophage activation. In addition to the proinflammatory classical activation, we also focused on interleukin (IL) 4 and 13 -induced alternative activation which is a significant macrophage phenotype in tissue repairing processes and in fibrosing diseases. PPARα agonists GW7647 and fenofibrate as well as PPARγ agonist GW1929 inhibited lipopolysaccharide-induced classical macrophage activation and production of the characteristic biomarkers of this phenotype, i.e. IL-6 and nitric oxide, in murine J774 macrophages. Remarkably, the PPARα agonists also inhibited IL-4 and IL-13 –induced expression of alternative activation markers arginase-1, fizz1 and mannose receptor 1 whereas the PPARγ agonist GW1929 enhanced their expression in J774 macrophages. The PPARα agonists GW7647 and fenofibrate also attenuated the production of alternative activation markers chemokine (C-C motif) ligand 13 and plateletderived growth factor in human THP-1 macrophages. The present findings show that PPARα and PPARγ agonists differently regulate classical and alternative macrophage phenotypes. Furthermore, PPARα activation was introduced as a novel concept to down-regulate alternative macrophage activation indicating that PPARα agonists have therapeutic potential in conditions associated with aberrant alternative macrophage activation such as fibrosing diseases.

Read accessible full text

Peroxisome proliferator-activated receptor alpha and gamma agonists differently regulate classical and alternative macrophage activation

Author: Paukkeri, Erja-Leena,Pekurinen, Antti,Moilanen, Eeva
Year: 2015
Source: https://trepo.tuni.fi/bitstream/10024/100210/1/peroxisome_proliferator-activated_2015.pdf
Immunome abolism 2015; 2: 1–11
abe an al e na i e mac ophage ac i a ion such as
ib osing diseases.
Keywo ds: Mac ophage pola iza ion, pe oxisome
p oli e a o -ac i a ed ecep o , ib osis
DOI 10.1515/immun-2015-0001
Recei ed Ma ch 2, 2015; accep ed Ma ch 23, 2015
1 In oduc ion
Mac ophages a e impo an e ec o cells in in lamma o y
esponses. They a e in ol ed in bac e ial in ec ions
and au oimmune diseases bu also in he low g ade
in lamma ion associa ed wi h obesi y and me abolic
synd ome. Mac ophages also ha e homeos a ic unc ions
and hey ac i a e healing p ocess associa ed wi h
in lamma ion and issue inju y [1-3]. To achie e hese
mul i o m asks, mac ophages a e p og ammed o display
dis inc pheno ypes in esponse o en i onmen al signals
[2-5]. Fo example, Th1 cy okine in e e on γ (IFNγ) and
oll-like ecep o 4 (TLR4) ligand lipopolysaccha ide (LPS)
igge classical, i.e. ype M1, ac i a ion o mac ophages,
which is ypical o bac e ial in ec ions and au oimmune
eac ions [6]. On he o he hand, Th2 cy okines in e leukin
(IL) 4 and 13 igge al e na i e, i.e. ype M2, ac i a ion,
which is associa ed wi h wound healing bu also wi h
he abe an immune esponses associa ed wi h o e -
ac i a ion o ib oblas s and subsequen ib osis [6,7].
Classical ac i a ion o mac ophages leads o he
elease o p oin lamma o y and an imic obial ac o s
including IL-6, IL-12, umou nec osis ac o (TNF)
and ni ic oxide (NO) p oduced by inducible ni ic
oxide syn hase (iNOS) pa hway. On he o he hand,
al e na i ely ac i a ed mac ophages exp ess ac o s ha
ha e been associa ed wi h ecogni ion o ex acellula
pa hogens and/o s imula ion o ib oblas s. Some o
Abs ac : Pe oxisome p oli e a o -ac i a ed ecep o
(PPAR) agonis s, ib a es and hiazolidinediones, a e
commonly used d ugs in he ea men o dyslipidemia and
diabe es. Thei a ge s, PPARα and PPARγ, ha e also been
shown o ha e a ole in he egula ion o in lamma o y
esponses linking me abolism and in lamma ion. In
he p esen s udy we in es iga ed he e ec s o PPAR
agonis s on mac ophage ac i a ion. In addi ion o he
p oin lamma o y classical ac i a ion, we also ocused
on in e leukin (IL) 4 and 13 -induced al e na i e
ac i a ion which is a signi ican mac ophage pheno ype
in issue epai ing p ocesses and in ib osing diseases.
PPARα agonis s GW7647 and eno ib a e as well as PPARγ
agonis GW1929 inhibi ed lipopolysaccha ide-induced
classical mac ophage ac i a ion and p oduc ion o he
cha ac e is ic bioma ke s o his pheno ype, i.e. IL-6 and
ni ic oxide, in mu ine J774 mac ophages. Rema kably,
he PPARα agonis s also inhibi ed IL-4 and IL-13 –induced
exp ession o al e na i e ac i a ion ma ke s a ginase-1,
izz1 and mannose ecep o 1 whe eas he PPARγ agonis
GW1929 enhanced hei exp ession in J774 mac ophages.
The PPARα agonis s GW7647 and eno ib a e also
a enua ed he p oduc ion o al e na i e ac i a ion
ma ke s chemokine (C-C mo i ) ligand 13 and pla ele -
de i ed g ow h ac o in human THP-1 mac ophages.
The p esen indings show ha PPARα and PPARγ agonis s
di e en ly egula e classical and al e na i e mac ophage
pheno ypes. Fu he mo e, PPARα ac i a ion was
in oduced as a no el concep o down- egula e al e na i e
mac ophage ac i a ion indica ing ha PPARα agonis s
ha e he apeu ic po en ial in condi ions associa ed wi h
Resea ch A icle Open Access
© 2015 E ja-Leena Paukke i e al., licensee De G uy e Open.
This wo k is licensed unde he C ea i e Commons A ibu ion-NonComme cial-NoDe i s 3.0 License.
E ja-Leena Paukke i, An i Peku inen, Ee a Moilanen
Pe oxisome p oli e a o -ac i a ed ecep o α
and γ agonis s di e en ly egula e classical and
al e na i e mac ophage ac i a ion
*Co esponding au ho : Ee a Moilanen: The Immunopha macology
Resea ch G oup, Uni e si y o Tampe e School o Medicine and
Tampe e Uni e si y Hospi al, Tampe e, Finland,
E-mail: ee a.moi[email p o ec ed]
E ja-Leena Paukke i, An i Peku inen: The Immunopha macology
Resea ch G oup, Uni e si y o Tampe e School o Medicine and
Tampe e Uni e si y Hospi al, Tampe e, Finland
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM
2   E ja-Leena Paukke i e al.
hese ac o s a e a ginase 1, chemokine (C-C mo i )
ligand 13 (CCL13), pla ele -de i ed g ow h ac o (PDGF),
mannose ecep o 1 (m c-1) and, in mu ine mac ophages,
ound in in lamma o y zone 1 ( izz1), o ins ance [4,8-
10]. Likewise, also in clinical se ings, al e na i ely
ac i a ed mac ophages ha e been linked o de ence
agains ex acellula pa hogens, and o esolu ion o
in lamma ion, wound healing and ib osis [11-13].
In addi ion o IL-4 and IL-13, pe oxisome p oli e a o -
ac i a ed ecep o γ (PPARγ) ligands ha e been ound o
pola ize mac ophages owa ds he al e na i e pheno ype
[14,15]. PPARs a e nuclea ecep o s ha ha e a c ucial
physiological ole in he egula ion o ene gy homeos asis.
PPARγ egula es he impo o glucose in o cells, and
PPARγ agonis s hiazolidinediones (TZDs) a e widely
used as pha macological agen s in he ea men o ype 2
diabe es. Ano he iso ype o PPARs, PPARα is linked o he
egula ion o lipid me abolism. Syn he ic ligands include
ib a es, which a e used o ea dyslipidemia. As compa ed
o PPARγ agonis s, less is known abou he possible
in ol emen o PPARα agonis s in he egula ion o immune
and in lamma o y esponses [16-19] and hei e ec s on
al e na i e ac i a ion o mac ophages emains unknown.
In he p esen s udy, we aimed o compa e he e ec s
o PPARα and PPARγ agonis s on classical and al e na i e
ac i a ion o mac ophages. We used LPS o a combina ion o
IL-4 and IL-13 o induce mac ophage pola iza ion o classical
o al e na i e pheno ype, espec i ely. The esul s show ha
PPARα and PPARγ agonis s di e en ly egula e mac ophage
pheno ypes, and in oduce PPARα ac i a ion as a no el
concep o down- egula e al e na i e mac ophage ac i a ion.
2 Ma e ials and me hods
2.1 Ma e ials
Reagen s we e ob ained as ollows: GW1929 and GW7647
om Toc is Bioscience (B is ol, UK), abbi polyclonal
β-ac in, a ginase 1 and STAT6 an ibodies and goa HRP-
conjuga ed an i- abbi and donkey HRP-conjuga ed an i-
goa polyclonal an ibodies om San a C uz Bio echnology
Inc. (San a C uz, CA, USA). pSTAT6 (Ty 641) an ibody
was om Calbiochem (Me ck Millipo e, Bille ica, MA,
USA) and PPARα and PPARγ an ibodies om Alexis
Biochemicals (Enzo Li e Sciences, Lausen, Swi ze land).
Recombinan mouse IL-4 and IL-13 and human IL-4
we e om R&D Sys ems (Minneapolis, MN, USA). O he
eagen s we e om Sigma-Ald ich Co. (S . Louis, MO, USA)
unless o he wise s a ed.
2.2 Cell cul u e
Mu ine J774A.1 mac ophages (Ame ican Type Cul u e
Collec ion, Manassas, VA, USA) we e cul u ed a 37°C
in 5% CO2 a mosphe e in Dulbecco’s modi ied Eagle’s
medium wi h Ul aglu amine1 (Lonza G oup L d, Basel,
Swi ze land) supplemen ed wi h 10% hea -inac i a ed
oe al bo ine se um (Lonza G oup L d), 100 U/ml
penicillin, 100 µg/ml s ep omycin and 250 ng/ml
ampho e icin B (In i ogen Co., Ca lsbad, CA, USA)
and ha es ed wi h ypsin-EDTA (In i ogen Co.).
Cells we e seeded on 24-well pla es o RNA ex ac ion,
ni i e and ELISA measu emen s and o p epa a ion o
cell lysa es o wes e n blo ing and on 96-well pla es
o XTT es . Con luen cul u es we e exposed o esh
cul u e medium con aining he compounds o in e es .
PPAR agonis s we e added o he medium oge he wi h
LPS o a combina ion o IL-4 and IL-13 unless o he wise
s a ed.
Human THP-1 p omonocy es (Ame ican Type Cul u e
Collec ion) we e cul u ed a 37°C in 5% CO2 a mosphe e
in RPMI 1640 (Lonza G oup L d) adjus ed o con ain
2 mM ʟ-glu amine (Lonza G oup L d), 10 mM HEPES
(Lonza G oup L d), 4.5 g/l glucose (Sigma-Ald ich
Co.) and 1.5 g/l bica bona e (Lonza G oup L d) and
supplemen ed wi h 10% hea -inac i a ed oe al bo ine
se um (Lonza G oup L d), 100 U/ml penicillin, 100 µg/
ml s ep omycin, 250 ng/ml ampho e icin B (In i ogen
Co.), and 0.05 mM 2-me cap oe hanol (Sigma-Ald ich
Co.). The cells we e di e en ia ed by adding pho bol es e
12-O- e adecanoylpho bol-13-ace a e (100 nM) (Sigma-
Ald ich Co.) a he ime o seeding on 24-well pla es.
Se en y- wo hou s a e he seeding he cul u es we e
con luen and hey we e exposed o esh cul u e medium
con aining he compounds o in e es . PPAR agonis s we e
added o he medium oge he wi h LPS o a combina ion
o IL-4 and IL-13 unless o he wise s a ed.
Cell iabili y a e ea men wi h combina ions o
LPS o cy okine mix u e and he es ed compounds was
assessed by modi ied XTT es (Cell p oli e a ion Ki II,
Roche Diagnos ics, Mannheim, Ge many) acco ding o he
manu ac u e ’s ins uc ions.
2.3 Ni i e de e mina ion
NO p oduc ion was de e mined by measu ing he
accumula ion o ni i e, a s able me aboli e o NO in
aqueous condi ion, in o he cul u e medium. The cul u e
medium was collec ed a indica ed ime poin s and ni i e
was measu ed by he G iess eac ion [20].
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM
PPARα agonis s supp ess al e na i e mac ophage ac i a ion   3
2.4 P epa a ion o cell lysa es o wes e n
blo ing
A indica ed ime poin s, he cells we e apidly
washed wi h ice-cold phospha e-bu e ed saline and
solubilized in cold lysis bu e con aining 10 mM T is-
base, pH 7.4, 5 mM EDTA, 50 mM NaCl, 1% T i on X-100,
0.5 mM phenylme hylsulphonyl luo ide, 1 mM sodium
o ho anada e, 20 μg/ml leupep in, 50 μg/ml ap o inin,
5mM NaF, 2 mM sodium py ophospha e and 10 μM
n-oc yl-β-D-glucopy anoside. A e incuba ion on ice
o 15 minu es, lysa es we e cen i uged (13 400 g, 4°C,
10 min), supe na an s we e collec ed and mixed 3:1
wi h SDS sample bu e (62.5 mM T is–HCl, pH 6.8, 10%
glyce ol, 2% SDS, 0.025% b omophenol blue and 5%
β-me cap oe hanol). The samples we e s o ed a -20°C
un il analysed. An aliquo o he supe na an was used o
de e mine p o ein concen a ion by he Coomassie blue
me hod [21].
2.5 Wes e n blo ing
P io o wes e n blo ing, samples we e boiled o 10
minu es and 20 μg o p o ein was loaded pe lane on
8% o 10% SDS-polyac ylamide gels and sepa a ed by
elec opho esis. P o eins we e ans e ed o Hybond
enhanced chemiluminescence ni ocellulose memb ane
(GE Heal hca e, Li le Chal on , Buckinghamshi e, UK).
A e he ans e , he memb ane was blocked in TBS/T
(20 mM T is-base pH 7.6, 150 mM NaCl, 0.1% Tween-20)
con aining 5% o non- a d y milk o 5% bo ine se um
albumin a oom empe a u e o 1 h and incuba ed
wi h he p ima y an ibody in he blocking solu ion a 4
°C o e nigh . The memb ane was washed wi h TBS/T,
incuba ed wi h he seconda y an ibody in he blocking
solu ion a oom empe a u e o 1 hou and washed.
Bound an ibody was de ec ed using Supe Signal Wes Pico
o Du a chemiluminescen subs a e (Pie ce, Rock o d, IL,
USA) and ImageQuan LAS 4000 mini imaging sys em (GE
Heal hca e). The chemiluminescen signal was quan i ied
wi h ImageQuan TL 7.0 image analysis so wa e (GE
Heal hca e).
2.6 RNA ex ac ion and quan i a i e
eal- ime PCR
A he indica ed ime poin s, cul u e medium was emo ed
and o al RNA ex ac ion o he cells was ca ied ou wi h
GenElu e™ Mammalian To al RNA Minip ep ki (Sigma-
Ald ich Co.). 100 ng o o al RNA was e e se- ansc ibed
o cDNA using TaqMan Re e se T ansc ip ion eagen s
and andom hexame s (Applied Biosys ems, Fos e Ci y,
CA, USA). cDNA ob ained om he e e se ansc ip ion
eac ion was dilu ed 1:20 wi h RNase- ee wa e and was
subjec ed o quan i a i e PCR using TaqMan Uni e sal
PCR Mas e Mix and ABI P ism 7000 sequence de ec ion
sys em (Applied Biosys ems).
P ime s and p obes o a ginase 1 and glyce aldehyde-
3-phospha e dehyd ogenase (GAPDH) we e op imized
acco ding o he manu ac u e ’s ins uc ions in
TaqMan Uni e sal PCR Mas e Mix P o ocol pa
numbe 4304449 e ision C and we e as ollows:
5’-TCCAAGCCAAAGTCCTTAGAGATTAT-3’,
5’-CGTCATACTCTGTTTCTTTAAGTTTTTCC-3’,
5’-CGCCTTTCTCAAAAGGACAGCCTCGA-3’
( o wa d and e e se p ime s and p obe o mouse
a ginase 1) and 5’-GCATGGCCTTCCGTGTTC-3’,
5’-GATGTCATCATACTTGGCAGGTTT-3’,
5’-TCGTGGATCTGACGTGCCGCC-3’ ( o wa d and e e se
p ime s and p obe o mouse GAPDH). The exp ession o
mouse PPARα, PPARγ, izz1 and m c-1 and human CCL13
and PDGF mRNA was measu ed by using TaqMan® Gene
Exp ession Assay (Mm00440939_m1, Mm01184322_m1,
Mm00445109_m1, Mm00485148_m1, Hs01033504_g1,
Hs00966522_m1, Applied Biosys ems).
PCR eac ion pa ame e s we e as ollows: incuba ion
a 50°C o 2 min, incuba ion a 95°C o 10 min, and
he ea e 40 cycles o dena u a ion a 95°C o 15 s and
annealing and ex ension a 60°C o 1 min. Each sample
was de e mined in duplica e.
The ela i e mRNA le els we e quan i ied and
compa ed using he ela i e s anda d cu e me hod as
desc ibed in Applied Biosys ems Use Bulle in numbe 2
(a ginase 1) o ΔC me hod (TaqMan® Gene Exp ession
Assays).
2.7 Enzyme-Linked Immunoso ben Assay
(ELISA)
Cul u e medium samples we e kep a -20°C un il assayed.
The concen a ions o IL-6 and CCL13 in cul u e medium
we e de e mined by ELISA acco ding o he manu ac u e ’s
ins uc ions using eagen s om R&D Sys ems Eu ope
(Abingdon, UK).
2.8 S a is ics
Resul s a e exp essed as mean + s anda d e o o mean
(SEM). When indica ed, s a is ical signi icance was
calcula ed by analysis o a iance ollowed by Dunne ’s
mul iple compa isons es o by unpai ed es wi h Welch
co ec ion. All he s a is ical analyses we e pe o med
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM
4   E ja-Leena Paukke i e al.
using G aphPad InS a e sion 3.10 o Windows
(G aphPad So wa e, San Diego, CA, USA). Di e ences
we e conside ed signi ican a p<0.05.
E hical app o al: The conduc ed esea ch is no
ela ed o ei he human o animals use.
3 Resul s
3.1 J774 mac ophages exp ess PPARs and
can ep esen classical and al e na i e ac i-
a ion pheno ypes
J774 mac ophages we e ound o exp ess PPARα and
PPARγ as de ec ed by wes e n blo ing and RT-qPCR
(Figu e 1). As shown in Figu es 2 and 3, he ac i a ion o
he mac ophages wi h LPS inc eased he exp ession o
classical ac i a ion ma ke s including IL-6 and inducible
ni ic oxide syn hase (iNOS) whe eas s imula ion wi h a
combina ion o IL-4 and IL-13 induced he exp ession o
al e na i e ac i a ion ma ke s a ginase 1, izz1 and m c-1.
The le els o a ginase 1, izz1 and m c-1 mRNA we e highes
a 36 h, 12 h and 12 - 24 h, espec i ely, a e he onse o
he in e leukin s imula ion (Figu e 2).
3.2 PPAR agonis s educed he le els o
classical ac i a ion ma ke s a e LPS-s imu-
la ion, bu had di e ing e ec s on al e na-
i e ac i a ion
PPARα agonis s GW7647 and eno ib a e and PPARγ
agonis GW1929 a enua ed classical mac ophage
ac i a ion as shown by educed iNOS exp ession (Figu e
3a) and NO and IL-6 p oduc ion (Figu e 3b) in J774
mac ophages exposed o LPS. The agonis s did no al e
he le els o classical ac i a ion ma ke s in he absence
Figu e 1 The exp ession o PPARα and PPARγ in J774 mac ophages. (a) P o eins we e ex ac ed and PPARα and PPARγ p o ein exp ession was
de e mined by wes e n blo ing. The gels shown a e ep esen a i es o h ee o he s wi h simila esul s. (b) To al RNA was ex ac ed and
he le els o PPARα and PPARγ mRNA we e analysed by RT-qPCR. The esul s we e no malized agains GAPDH mRNA and he le el o PPARα
mRNA was compa ed o ha o PPARγ (n=6).
Figu e 2 Time-dependen exp ession o al e na i e ac i a ion
ma ke s in J774 mac ophages. The cells we e s imula ed wi h IL-4
and IL-13 and incuba ions we e e mina ed a indica ed ime poin s
and o al RNA was ex ac ed. A ginase 1 (a), izz1 (b) and m c-1 (c)
mRNA we e de e mined by RT-qPCR. The esul s we e no malized
agains GAPDH mRNA. Resul s ep esen he mean ± SEM (n=4).
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM
PPARα agonis s supp ess al e na i e mac ophage ac i a ion   5
and eno ib a e also dec eased he exp ession o a ginase
1 p o ein (Figu e 7).
3.3 PPARα agonis s educed he le els o
al e na i e ac i a ion ma ke s also in human
THP-1 mac ophages
Be o e e alua ing he e ec s o PPARα agonis s on
al e na i e ac i a ion in human mac ophages, we
examined CCL13 and PDGF mRNA ansc ip ion ollowing
IL-4 s imula ion, as ma ke s o al e na i e ac i a ion [3,22].
In THP-1 mac ophages IL-4-enhanced CCL13 and PDGF
exp ession, and hei mRNA le els con inued o inc ease
a leas un il 36 hou s a e he addi ion o IL-4 (Figu e 8).
GW7647 and eno ib a e clea ly dec eased IL-4–induced
CCL13 exp ession as shown by educed cellula le els o
CCL13 mRNA and dec eased amoun s o CCL13 p o ein in
he cul u e medium (Figu e 9a-b). GW7647, and o a lesse
o LPS o a ec cell iabili y a he concen a ion used as
de e mined by XTT es (da a no shown).
To in es iga e i PPARs a e able o induce al e na i e
ac i a ion in mac ophages, we es ed he e ec s o he
PPAR agonis s on he exp ession o a ginase 1. As expec ed,
he PPARγ agonis GW1929 inc eased he exp ession o
a ginase 1 mRNA when measu ed a e 24 h incuba ion.
In con as , he PPARα agonis s GW7647 and eno ib a e
dec eased he le els o a ginase 1 (Figu e 4).
Nex , we es ed he e ec o PPAR agonis s on IL-4
+ IL-13 -induced al e na i e pheno ype in J774 cells. The
selec i e PPARγ agonis GW1929 inc eased IL-4 + IL-13
-induced p o ein exp ession o a ginase 1, and mRNA
le els o izz1 and m c-1, when de e mined a e 24 hou
incuba ion (Figu e 5). In con as , he PPARα agonis s
dec eased IL-4 + IL-13 -induced le els o a ginase 1, izz1 and
m c-1 mRNA, when de e mined a e 24 hou incuba ion
(Figu e 6). In line wi h he esul s a mRNA le el, GW7647
Figu e 3 PPARα and PPARγ agonis s supp essed classical mac ophage ac i a ion. (a) Cells we e ea ed wi h he PPARα agonis s GW7647 o
eno ib a e o wi h he PPARγ agonis GW1929 and s imula ed wi h LPS. A e 24 h incuba ion, p o eins we e ex ac ed and iNOS exp ession
was analysed by wes e n blo ing. β-ac in was used as a loading con ol. (b) Cells we e ea ed wi h he PPARα agonis s GW7647 o eno i-
b a e o wi h he PPARγ agonis GW1929 and s imula ed wi h LPS. A e 24 h incuba ion, ni i e accumula ed in o he cul u e medium was
measu ed by G iess eac ion as a ma ke o NO p oduc ion. IL-6 in he cul u e medium was measu ed by ELISA. Resul s ep esen he mean +
SEM (n=4). ** = p<0.01 as compa ed o cells cul u ed wi h LPS alone.
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM

6   E ja-Leena Paukke i e al.
ex end eno ib a e, also dec eased PDGF mRNA le els in
THP-1 cells (Figu e 9c).
3.4 PPAR agonis s did no a ec he phos-
pho yla ion o STAT6
STAT6 has been shown o be an impo an cy osolic
media o o ansc ip ional e ec s o IL-4 and IL-13.
The e o e we in es iga ed he e ec s o PPAR agonis s on
STAT6 phospho yla ion (i.e. ac i a ion). Cos imula ion
wi h IL-4 and IL-13 induced he phospho yla ion o
STAT6 peaking a 30 minu es a e addi ion o IL-4 and
IL-13 in J774 mac ophages (Figu e 10a). As seen in Figu e
10b-c, nei he eno ib a e no GW7647 modi ied he
phospho yla ion o STAT6 in J774 o THP-1 mac ophages.
4 Discussion
The p esen indings in oduce PPARα agonis s as
compounds able o down- egula e al e na i e mac ophage
ac i a ion, while PPARγ agonis s enhanced he al e na i e
pheno ype o mac ophages. Fu he , bo h PPARα and
PPARγ agonis s a enua ed he classical mac ophage
ac i a ion. The al e na i e ac i a ion o adipose issue
mac ophages has been p oposed o p o ec lean people
om insulin esis ance and o he obesi y-linked
me abolic mani es a ions. Thus, PPARγ agonis s and
o he compounds ha pola ize mac ophages owa ds he
Figu e 5 PPARγ agonis GW1929 enhanced he exp ession o al e na-
i e ac i a ion ma ke s in J774 mac ophages. Cells we e ea ed wi h
GW1929 and s imula ed wi h IL-4 and IL-13 o 24 hou s. (a) P o eins
we e ex ac ed and he le els o a ginase 1 we e analysed by wes e n
blo ing. β-ac in was used as a loading con ol. (b-c) To al RNA was
ex ac ed and subjec ed o RT-qPCR. The esul s we e no malized
agains GAPDH mRNA. Resul s ep esen he mean + SEM (n=4).
** = p<0.01 as compa ed o cells cul u ed wi h IL-4 and IL-13.
Figu e 4 PPARα agonis s supp essed, bu PPARγ agonis s enhanced
he exp ession o he classical ma ke o al e na i e ac i a ion, i.e.
a ginase 1, in J774 mac ophages. Cells we e ea ed wi h he PPARα
agonis s GW7647 o eno ib a e o wi h he PPARγ agonis GW1929
o 24 hou s. To al RNA was ex ac ed and a ginase 1 mRNA was
de e mined by RT-qPCR. The esul s we e no malized agains GAPDH
mRNA. Resul s ep esen he mean + SEM (n=4). * = p<0.05 and ** =
p<0.01 as compa ed o un ea ed cells.
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM
PPARα agonis s supp ess al e na i e mac ophage ac i a ion   7
al e na i e pheno ype may be bene icial in obesi y ela ed
me abolic diso de s [23,24]. In con as , compounds
able o inhibi al e na i e mac ophage pheno ype may
ha e a he apeu ic e ec in ib osing diseases, which
a e complica ed wi h abe an ly enhanced ac i a ion o
al e na i e mac ophages [25-27].
Al e na i ely ac i a ed mac ophages ac i a e
ib oblas s o p oli e a e, mig a e o he ib osing a ea and
o p oduce ex acellula ma ix componen s esul ing in
ib oblas -popula ed g anula ion issue [28]. Howe e ,
he mechanisms how his occu s a e no known in de ail.
Acco ding o p e ious epo s, sys emic scle osis (SSc) is
an example o he diseases whe e mac ophages induce
p o ib o ic ac ion o ib oblas s. Ho me and He zog
showed in 2010 ha mos o he mac ophages in he
Figu e 6 PPARα agonis s supp essed he exp ession o al e na i e
ac i a ion ma ke s in J774 mac ophages. Cells we e ea ed wi h
GW7647 o eno ib a e and s imula ed wi h IL-4 and IL-13 o 24
hou s. To al RNA was ex ac ed and a ginase 1 (a), izz1 (b) and m c-1
(c) mRNA was de e mined by RT-qPCR. The esul s we e no malized
agains GAPDH mRNA. Resul s ep esen he mean + SEM (n=4). * =
p<0.05 and ** = p<0.01 as compa ed o cells cul u ed wi h IL-4 and
IL-13.
Figu e 7 PPARα agonis s supp essed a ginase 1 p o ein exp es-
sion in J774 mac ophages. Cells we e ea ed wi h GW7647 (a) o
eno ib a e (b) and s imula ed wi h IL-4 and IL-13 o 24 hou s.
P o eins we e ex ac ed and he le els o a ginase 1 we e analysed
by wes e n blo ing. β-ac in was used as a loading con ol. Resul s
ep esen he mean + SEM (n=4). ** = p<0.01 as compa ed o cells
cul u ed wi h IL-4 and IL-13.
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM
8   E ja-Leena Paukke i e al.
lung issue o pa ien s wi h SSc-associa ed in e s i ial
lung disease display ma ke s o al e na i e mac ophage
ac i a ion [27]. Also in ano he epo , m c-1 exp ession
was ele a ed in pe iphe al blood mononuclea cells
(PBMCs) om pa ien s wi h limi ed cu aneous SSc and
pulmona y hype ension when compa ed o heal hy
con ols [25]. Addi ionally, pa ien s wi h ei he limi ed o
di use cu aneous SSc ha e been epo ed o ha e ele a ed
se um le els o al e na i e mac ophage- ela ed cy okines
IL-4, IL-10 and IL-13 [25,26]. IL-13 ecep o an agonis s
also a enua ed skin and lung ib osis in expe imen al
models. Acco dingly, ea men wi h IFN-γ (which d i es
mac ophages owa ds M1 pheno ype) has been shown
o imp o e skin sco es in pa ien s wi h SSc [31]. Mos
in e es ingly, an a ginase inhibi o , pi enidone, has
been p o en o be bene icial in pa ien s wi h idiopa hic
pulmona y ib osis when compa ed o placebo in wo
mul icen e s udies [32]. Pi enidone was app o ed o
he ea men o idiopa hic pulmona y ib osis in Eu ope
Figu e 8 Time-dependen exp ession o al e na i e ac i a ion
ma ke s in THP-1 cells. The cells we e s imula ed wi h IL-4 and
incuba ions we e e mina ed and o al RNA was ex ac ed a indica-
ed ime poin s. CCL13 (a) and PDGF (b) mRNA was de e mined by
RT-qPCR. The esul s we e no malized agains GAPDH mRNA. Resul s
ep esen he mean ± SEM (n=4).
Figu e 9 PPARα agonis s supp essed he exp ession o al e na i e
ac i a ion ma ke s in THP-1 cells. (a, c) Cells we e ea ed wi h
GW7647 o eno ib a e and s imula ed wi h IL-4 o 24 hou s. To al
RNA was ex ac ed and CCL13 (a) and PDGF (c) mRNA was de e mi-
ned by RT-qPCR. The esul s we e no malized agains GAPDH mRNA.
(b) Cells we e ea ed wi h GW7647 o eno ib a e and s imula ed
wi h IL-4. A e 24 h incuba ion, CCL13 accumula ed in o he cul u e
medium was measu ed by ELISA. Resul s ep esen he mean + SEM
(n=4). ** = p<0.01 as compa ed o cells cul u ed wi h IL-4.
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM
PPARα agonis s supp ess al e na i e mac ophage ac i a ion   9
TNF [17,33,34]. In addi ion, PPARγ agonis s ha e been
epo ed o shi he pola iza ion o mac ophages owa ds
he al e na i e pheno ype [14,15] and ha was also seen in
he p esen s udy. In e es ingly, we epo he e ha PPARα
agonis s ha e an opposi e e ec on M2 pola iza ion.
To ou knowledge, he p esen s udy is he i s epo
showing he inhibi o y e ec s o PPARα agonis s on he
al e na i e ac i a ion o mac ophages indica ing ha
PPARα and PPARγ agonis s di e en ly egula e al e na i e
mac ophage ac i a ion.
The di e si y o mac ophage pheno ypes has bes
been desc ibed in mouse mac ophages. Some o he
known ma ke s o al e na i e ac i a ion, e.g. izz1, a e
exp essed only in mice [35] and some o he ma ke s, like
a ginase 1, a e impo an in i o bu become silenced
apidly in ex i o condi ions in human cells [36,37]. Also
as epo ed in his s udy, J774 mac ophages inc eased
Figu e 10 The e ec s o PPARα agonis s on STAT6 phospho yla ion in J774 and THP-1 cells. (a) Cells we e s imula ed wi h IL-4 and IL-13 and
incuba ions we e e mina ed a indica ed ime poin s. P o eins we e ex ac ed and he le els o pSTAT6 we e analysed by wes e n blo ing.
To al STAT6 was used as a loading con ol. The gel shown is a ep esen a i e o h ee o he s wi h simila esul s. (b) J774 mac ophages we e
p eincuba ed wi h he PPARα agonis s o he ehicle o an hou be o e addi ion o IL-4 and IL-13. A e 30 min incuba ion wi h IL-4 and IL-13
p o eins we e ex ac ed and he le els o pSTAT6 we e analysed by wes e n blo ing. (c) THP-1 cells we e p eincuba ed wi h he PPARα ago-
nis s o he ehicle o an hou be o e addi ion o IL-4. A e 30 min incuba ion wi h IL-4, p o eins we e ex ac ed and he le els o pSTAT6
we e analysed by wes e n blo ing. (b,c) To al STAT6 and β-ac in we e used as loading con ols. Resul s ep esen he mean + SEM (n=4). **
= p<0.01 as compa ed o cells cul u ed wi h IL-4 and IL-13 (a,b) o IL-4 (c).
in 2011 and may be bene icial also in o he ib osing
diseases including SSc. A he momen , he e a e no
speci ic ea men s a ge ing he pa hophysiology o he
ib osing p ocesses in SSc o ela ed diseases bu mos
o he he apies used ac as immunomodula o s, like
me ho exa e, cyclophosphamide and aza hiop ine, o
asodila o s, like calcium channel blocke s, p os acyclin
analogs, elmisa an, phosphodies e ase inhibi o s and
endo helin I an agonis s. Howe e , he e icacy o hese
d ugs is e y limi ed and be e ea men op ions a e
c i ically needed.
PPARα agonis s ib a es and PPARγ agonis s TZDs a e
in clinical use o he ea men o me abolic diso de s.
In line wi h he p esen esul s, bo h ib a es and TZDs
ha e also shown o dec ease he p oduc ion o IFNγ o
LPS –induced p oin lamma o y media o s ypical o
classical mac ophage ac i a ion like iNOS, NO, IL-6 and
B ough o you by | Tampe e Uni e si y Lib a y
Au hen ica ed
Download Da e | 12/1/16 2:18 PM